US infant formula supply is ‘safe,’ FDA says after looking for potential contaminants

The FDA has declared the U.S. infant formula supply safe after conducting targeted testing for potential contaminants, providing reassurance to parents still scarred by the 2022 formula shortage that left shelves empty for months.

The agency's review was prompted by routine surveillance that flagged a potential contamination concern in a specific manufacturing facility. Rather than issuing a broad warning that could trigger panic buying, the FDA conducted targeted testing and determined that no contaminated product had reached the market.

The approach marks a departure from 2022, when the FDA's handling of the Abbott Nutrition contamination was widely criticized as too slow and too opaque. This time, the agency appears to have learned from its mistakes — conducting thorough testing before making public statements and coordinating with manufacturers to ensure supply continuity.

The 2022 shortage, caused by the closure of Abbott's Michigan plant after bacterial contamination was discovered, exposed the fragility of the U.S. formula supply. A single facility produced roughly 20% of the nation's infant formula, and its closure created cascading shortages that took months to resolve.

Since then, the FDA has implemented new monitoring protocols, and Congress has passed legislation requiring better supply chain tracking and diversification of manufacturing sources. Whether those reforms are sufficient won't be clear until the next crisis tests them.

**What This Means For You:** If you're a parent relying on formula, the system is more resilient than it was four years ago — but still not as resilient as it should be. The FDA handled this potential issue competently, which is progress. Keep a reasonable supply on hand (two to four weeks), but don't hoard — that's what creates the shortages in the first place.